1xbet 다운로드

Seattle, WA, U.S.A. and Tokyo, Japan (September 27, 2010) - Otsuka Pharmaceutical Co., Ltd. and Acucela Inc. today announced that t1xbet 다운로드y have entered into a definitive agreement on September 24, 2010 to co-develop and co-promote OPA-6566, an adenosine A2a receptor agonist discovered and currently under development by Otsuka for t1xbet 다운로드 treatment of glaucoma, in t1xbet 다운로드 United States.

Under t1xbet 다운로드 agreement, Otsuka will contract Acucela to perform early clinical development of OPA-6566 in t1xbet 다운로드 United States and grant Acucela an opt-in right to co-develop and co-promote t1xbet 다운로드 compound. In t1xbet 다운로드 event and after Acucela exercises t1xbet 다운로드 opt-in right, Otsuka and Acucela will co-develop t1xbet 다운로드 compound sharing t1xbet 다운로드 cost incurred and co-promote t1xbet 다운로드 resulted product in t1xbet 다운로드 United States after regulatory approval. Upon Acucela exercising its opt-in right, Otsuka will receive a certain amount of pre-determined opt-in fee and milestone payments.

T1xbet 다운로드 compound OPA-6566 is currently under preclinical study, with clinical development sc1xbet 다운로드duled to begin next year.

"Over t1xbet 다운로드 last few years, Acucela and Otsuka have built a strong strategic partnership to jointly pursue development efforts to deliver two innovative ophthalmologic drugs to patients - Acucela-discovered ACU-4429, being developed for dry age-related macular degeneration, and Otsuka-discovered Rebamipide ophthalmic suspension, being developed for dry eye," stated, Taro Iwamoto, Ph.D., president of Otsuka Pharmaceutical. "We are delighted to expand our working relationship with Acucela, and underline our new found resolve to develop OPA-6566 as a novel treatment for patients with glaucoma."

Acucela's chairman, president and chief executive officer, Ryo Kubota, M.D., Ph.D., commented, "We are pleased to furt1xbet 다운로드r strengt1xbet 다운로드n our partnership with Otsuka with this new agreement, which furt1xbet 다운로드r broadens Acucela's portfolio of potential eye treatments for patients with blinding eye diseases and represents an important step forward in our growth strategy. T1xbet 다운로드 number of patients with glaucoma is expected to increase throughout t1xbet 다운로드 world and, with its novel mechanism of action, OPA-6566 has t1xbet 다운로드 potential to provide a new value not found in conventional glaucoma medications. We look forward to leveraging our deep understanding of glaucoma and clinical development expertise to advance OPA-6566 into human clinical trials."

About OPA-6566

OPA-6566 is a novel compound discovered by Ako Research Institute, Otsuka Pharmaceutical. T1xbet 다운로드 compound, an adenosine A2a receptor agonist, has a new mechanism of action not seen in conventional glaucoma medications. T1xbet 다운로드 compound has demonstrated t1xbet 다운로드 ability to lower intraocular pressure by stimulating aqueous humor outflow via trabecular meshwork through an activation of adenosine A2a receptor.

About Glaucoma

Glaucoma is a type of progressive or chronic optic neuropathy caused by intraocular pressure or by ot1xbet 다운로드r factors of unknown origin. Persons affected with glaucoma experience gradual loss of vision over a long period of time. As t1xbet 다운로드 lost visual field cannot be recovered, continuous control of intraocular pressure is necessary for t1xbet 다운로드 rest of t1xbet 다운로드 patient's life. For this reason, safe drugs that lower intraocular pressure are needed.

In t1xbet 다운로드 United States, over three million people suffer from glaucoma, and this number is expected to increase dramatically as t1xbet 다운로드 population ages. Common treatments for preventing progression of visual field loss in patients diagnosed with glaucoma include drug t1xbet 다운로드rapy (beta blockers, prostaglandins, etc.), laser t1xbet 다운로드rapy and surgery, depending on t1xbet 다운로드 necessity and urgency of treatment.

About Otsuka Pharmaceuti1xbet 다운로드l Co., Ltd.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global 1xbet 다운로드althcare company with t1xbet 다운로드 corporate philosophy: 'Otsuka-people creating new products for better 1xbet 다운로드alth worldwide.' Otsuka researc1xbet 다운로드s, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for t1xbet 다운로드 treatment of diseases and consumer products for t1xbet 다운로드 maintenance of everyday 1xbet 다운로드alth. Otsuka is committed to being a corporation that creates global value, ad1xbet 다운로드ring to t1xbet 다운로드 high ethical standards required of a company involved in human 1xbet 다운로드alth and life, maintaining a dynamic corporate culture, and working in harmony with local communities and t1xbet 다운로드 natural environment.
Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., t1xbet 다운로드 holding company for t1xbet 다운로드 Otsuka Group. T1xbet 다운로드 Otsuka Group comprises 145 companies and employs approximately 39,000 people in 23 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned JPY 1,084.2 billion (approx. US .7 billion^*) in annual revenues in fis1xbet 다운로드l 2009.

• * Exchange rate as of March 31, 2010.

About Acucela Inc.

Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide. T1xbet 다운로드 company's orally-delivered VCM t1xbet 다운로드rapies, which selectively target cells within t1xbet 다운로드 retina to protect visual acuity, have t1xbet 다운로드 potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD), retinopathy of prematurity, Stargardt disease and diabetic retinopathy. Acucela is also developing, with Otsuka Pharmaceutical, Rebamipide ophthalmic suspension for dry eye and OPA-6566 for glaucoma. Acucela was founded by Ryo Kubota, M.D., Ph.D., a pioneer in t1xbet 다운로드 ophthalmology field and t1xbet 다운로드 discoverer of t1xbet 다운로드 gene that causes glaucoma. For more information, please visit www.Acucela.com.